Aethlon Medical Inc. has announced a significant advancement in its clinical trial involving the Hemopurifier, a medical device aimed at treating solid tumors that do not respond to anti-PD-1 antibodies. As of June 18, 2025, the second patient has been treated in this ongoing safety, feasibility, and dose-finding trial at the Royal North Shore Hospital/University of Sydney. The trial, which focuses on patients with stable or progressive disease after monotherapy with Keytruda® or Opdivo®, will involve approximately 18 participants. The primary endpoint is to assess adverse events and changes in safety lab tests during the Hemopurifier treatment period. The study will also explore the number of treatments required to decrease extracellular vesicle concentrations and its potential impact on enhancing anti-tumor T cell activity. Results from these exploratory analyses are expected to inform the design of a future Premarket Approval study. The trial's progress and any resulting safety data will be reviewed by a Data Safety Monitoring Board (DSMB) after the enrollment of the third patient. Results have not yet been presented and are anticipated in the future.